Whether you need assistance with one part of your clinical trial or a full-service UK CRO, PHARMExcel supports sponsors to design and deliver robust, patient centred nephrology and renal disease clinical trials. We work with biotechs, medtech companies, charities and NHS or academic sponsors, providing agile, hands on support from early feasibility through to close out and reporting.
Nephrology and renal disease clinical trials explained
Nephrology clinical trials are essential for improving care in conditions such as chronic kidney disease, diabetic kidney disease, acute kidney injury, IgA nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis and a wide range of other rare renal and glomerular disorders. These studies often involve complex endpoints, close safety oversight and patient populations with significant comorbidities, including cardiovascular disease, diabetes and hypertension. Trial design must therefore balance scientific rigour with procedures and visit schedules that are realistic for patients, investigators and specialist renal centres.
Why nephrology trials need specialist expertise
Renal studies can be difficult to design and deliver because kidney disease is rarely straightforward. Patients may present with overlapping conditions, fluctuating renal function, heavy treatment burden and complications that affect eligibility, safety monitoring and endpoint selection. In glomerular and rare renal diseases, the challenge is often even greater, with smaller patient populations, highly specialised care pathways and the need for close collaboration with experienced nephrologists and referral centres.
Endpoints in nephrology trials may include proteinuria reduction, estimated glomerular filtration rate (eGFR), renal biomarkers, dialysis-related outcomes and longer term measures of kidney disease progression. Studies may also depend on careful urine collection, consistent sample handling and clear site processes to ensure that data are reliable and clinically meaningful. In acute and hospital-based renal studies, operational complexity can increase further because patients may be critically unwell, unstable or being treated across multiple specialties.
Working with a CRO that understands these practical and clinical nuances helps to reduce avoidable amendments, improve protocol feasibility and maintain data quality throughout the study.
"It has been a pleasure working with Yvanne and the team. PHARMExcel has been able to work with our clinical research teams to provide bespoke support for a number of trials, including phase 1 trials: the personal approach and attention to detail have given us confidence to ensure patient safety and manage the risks of the Trust acting as Sponsor in particular for the early phase trials."
Prof Saul Faust-Sponsor and Karen Underwood, University Hospital Southampton
Our approach as your nephrology CRO partner
Sponsors choose PHARMExcel when they need a partner that can operate as an extension of their own team rather than a distant service provider. As a smaller organisation, we offer direct access to experienced senior staff and continuity of the same core project team throughout the life of your nephrology trial. This allows for faster responses, informed discussions around risk and mitigation, and a collaborative approach when challenges arise.
Our work is underpinned by a formal quality management system and adherence to GCP, but we apply these standards in a way that remains flexible and proportionate to the needs of each study. We take time at the outset to understand your programme, internal ways of working and expectations for communication and reporting. For overseas sponsors, our knowledge of NHS and academic research environments helps to bridge the gap between global plans and UK site realities.
Commercially, our aim is to give you clarity and control. We provide transparent, itemised budgets and can shape our involvement around your internal capabilities, from full service nephrology CRO support to focused assistance with defined aspects of your programme.
Governance and oversight across specialist renal networks
Nephrology studies often depend on access to the right specialist centres, experienced investigators and site teams that understand the demands of renal research. PHARMExcel brings governance and oversight to this process by helping sponsors identify the most appropriate nephrology clinics, renal units and centres of excellence for their protocol, based on patient population, site capability and study complexity.
Where studies involve specialist procedures, complex sample collection or close monitoring of renal endpoints, we work with sponsors and sites to ensure those requirements are embedded through the right network of centres and partners. Our role is not to perform these procedures directly, but to provide the governance, oversight and coordination needed to ensure they are delivered consistently and in line with protocol requirements.
For studies involving rare renal diseases, glomerular disorders, vulnerable patient populations or harder to reach referral pathways, this network-led approach is particularly valuable. It allows sponsors to plan realistic site strategies and referral routes while maintaining close oversight of timelines, patient burden and operational risk.
Renal endpoints, assessments and study feasibility
For each new study, we work with sponsors and investigators to test core assumptions, sense check eligibility criteria and ensure visit schedules and assessments can be delivered reliably at the proposed sites. Because we understand the pressures on renal services, we focus on pragmatic solutions that support site engagement, feasible recruitment pathways and high quality data rather than idealised but impractical designs.
This is especially important in nephrology trials where proteinuria, eGFR, renal biomarkers, urine collection, dialysis-related scheduling or long term follow up can create a significant burden for patients and study teams. A well planned protocol does more than satisfy scientific objectives – it also needs to fit real clinic pathways, site capacity and the lived experience of the patient population.
As a specialist UK CRO, we are particularly well placed to support sponsors who are new to the UK research environment. We provide clear, candid feedback on feasibility, realistic timelines and the types of centres most suited to your protocol, helping you to plan a trial that works on paper and in practice.
Discuss your next nephrology study with us
Whether you are planning an early phase renal trial in the UK or expanding an existing programme into new sites, PHARMExcel can help you assess feasibility, refine your protocol and plan delivery. To explore how our nephrology and renal diseases CRO services could support your next study, contact our team to arrange an initial discussion.
Nephrology and renal diseases CRO FAQs
What does a nephrology CRO do for sponsors?
A nephrology CRO provides specialist clinical trial governance and oversight for studies in kidney and renal diseases. For sponsors, this can include feasibility assessments, protocol review, regulatory and ethics submissions, project management, monitoring, safety oversight, data management and operational coordination across specialist renal sites. A CRO with nephrology experience understands the procedures, endpoints and patient considerations involved and can help translate that into a realistic, deliverable study plan.
Which renal conditions can PHARMExcel support?
PHARMExcel can support renal clinical trials across a broad range of indications, including chronic kidney disease, diabetic kidney disease, acute kidney injury and a range of rare renal and glomerular disorders. This includes studies where specialist nephrology input, referral pathways and experienced renal centres are central to successful delivery. We work with sponsors to understand the target population, standard of care and study objectives, then align the trial with the most appropriate specialist centres and site pathways.
How does PHARMExcel approach recruitment in nephrology trials?
PHARMExcel does not directly recruit patients. Instead, we provide governance and oversight of site-level recruitment by helping sponsors identify the right sites, assess realistic recruitment pathways and work closely with investigators and research teams who know the local patient population. This is particularly important in nephrology studies, where comorbidities, referral patterns and the burden of participation can all influence enrolment and retention.
Can PHARMExcel oversee studies involving specialist renal assessments?
Yes. Many nephrology trials depend on specialised assessments and procedures such as urine collection, renal biomarker monitoring, dialysis-related scheduling or complex follow up pathways. PHARMExcel does not perform these assessments directly, but we provide governance and oversight by helping sponsors connect with sites and centres that have the right expertise, processes and infrastructure in place to deliver them consistently.
What rare renal and glomerular diseases can PHARMExcel oversee?
PHARMExcel can provide governance and oversight for trials in a wide range of rare renal and glomerular conditions, including IgA nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis and other low prevalence kidney disorders where referral pathways and specialist centres are critical to study delivery. In these settings, our role is to help sponsors align their trial with the right nephrology expertise, site network and operational approach so that complex studies remain feasible and patient centred.
What endpoints and assessments are common in nephrology clinical trials?
Nephrology studies often rely on a combination of clinical and laboratory endpoints, depending on the indication and study phase. Common examples include proteinuria, estimated glomerular filtration rate (eGFR), renal biomarkers, dialysis-related outcomes and longer term measures of kidney disease progression. Trials may also require structured urine collection, careful sample handling and consistent site processes to ensure that the resulting data are robust, interpretable and clinically meaningful.
How does PHARMExcel ensure quality and regulatory compliance in nephrology trials?
Our work is guided by a formal quality management system and adherence to GCP. For each nephrology study, we apply processes that are proportionate to the risk profile of the trial while maintaining clear oversight of site activity, protocol compliance, safety reporting and data quality. We also support sponsors with regulatory and ethics submissions and help ensure the study is delivered in line with UK regulatory expectations.
How does working with a smaller UK CRO benefit nephrology studies?
Working with a smaller CRO gives sponsors direct access to experienced senior staff, continuity of the same core team and shorter communication lines throughout the study. In nephrology trials, where protocols can be complex and site realities vary, this helps sponsors make faster, better informed decisions. Our familiarity with NHS and academic environments also helps align renal studies with real world site capacity and patient pathways.